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ABSTRACT 
MicroRNAs (miRNAs, miRs) are 18-24 nucleotide single-stranded RNAs that 
bind to complementary sites in the 3’ untranslated region (UTR) of their mRNA targets.  
They act together with the RNA-induced silencing complex (RISC) to post-
transcriptionally regulate target gene expression by either repressing translation or 
directly cleaving mRNA targets.  The polycistronic miR-17-92 cluster, which encodes 
miR-17, miR-18a, miR-19a, miR-20a, miR-19b, and miR-92a, is overexpressed in 
several solid tumors and hematopoietic malignancies.  Recently, it was shown that miR-
17-92 is overexpressed in leukemias arising from chromosomal translocations involving 
the Mixed Lineage Leukemia (MLL) gene.  Since MLL fusion leukemias are categorized 
as being particularly aggressive, discovering targets of the miR-17-92 cluster may shed 
light on potential novel therapeutics. 
In the present study, we used target gene prediction algorithms to predict potential 
targets of miRNAs within the miR-17-92 cluster.  WEE1, a kinase that inhibits cell cycle 
progression, was identified as a possible target of five of the six miRNAs of the cluster.  
We hypothesized that high miR-17-92 expression in MLL fusion leukemias causes 
downregulation of WEE1, which promotes cell cycle progression and contributes to 
leukemogenesis. 
Through luciferase reporter assays and mutagenesis studies, we found that miR-
17, miR-20a, and miR-18a specifically target nucleotides 465 to 487 of the 3’ UTR of 
 ix 
WEE1, while miR-19a and miR-19b exert control on WEE1 by targeting nucleotides 
1069 to 1091.  Surprisingly, we saw no significant increase in endogenous miR-17 or 
miR-19a expression as detected by TaqMan MicroRNA Assays in the established MLL 
fusion leukemia cell lines we tested (MV-4-11, RS4;11, THP-1, MonoMac6) as 
compared to the non-MLL fusion leukemia cell lines (K-562, HL-60, U-937).  We 
believe that miR-17-92 expression levels may be dependent on factors in addition to the 
presence of a MLL fusion protein, especially in cell lines.  Notably, while we did not 
detect a direct relationship between MLL rearrangement status and miR-17-92 
expression, we observed a negative correlation between endogenous miR-17 or miR-19a 
expression and endogenous WEE1 protein expression as detected by Western blot 
analysis in the same panel of cell lines.  The results of this project suggest that WEE1 is a 
valid biological target of the miR-17-92 cluster in leukemia.
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CHAPTER 1 
LITERATURE REVIEW 
Mixed Lineage Leukemia 
The Mixed Lineage Leukemia (MLL) gene was first identified for its involvement 
in chromosomal translocations at chromosome 11, band q23 that cause acute lymphoid 
leukemias, acute myeloid leukemias, or mixed lineage leukemias, also known as 
myeloid-lymphoid leukemias1.  Chromosomal rearrangements between nonhomologous 
chromosomes create an in-frame fusion between MLL and one of more than 60 different 
fusion partners2 (Figure 1A).  A chimeric protein is produced in which the amino-
terminus of MLL is fused with the carboxyl-terminus of the fusion partner3. 
MLL fusion partner genes encode either nuclear proteins or cytoplasmic proteins, 
with different functions.  Over 80% of MLL fusion leukemias possess a MLL fusion 
partner gene that encodes a nuclear protein such as AF4, AF9, ENL, ELL, AF10, and 
AF5q314.  Many of these nuclear fusion partners are normally present in a transcriptional 
elongation complex, while others are transcription factors.  Many of the cytoplasmic 
fusion partners have the ability to dimerize or multimerize.  Certain fusion partners are 
more prevalent in certain types of leukemia.  For example, MLL-AF4 in more common in 
acute lymphoid leukemia5, while MLL-AF9 is more common in acute myeloid leukemia. 
Leukemias arising from chromosomal translocations of the MLL gene account for 
5 to 10% of all human acute leukemias6.  MLL rearrangements are the most common 
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 Figure 1. Mixed Lineage Leukemia 
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(A) Wild-type MLL and the MLL fusion protein after undergoing chromosomal 
translocation.  (B) Event-free survival for patients with wild-type MLL and various 
MLL rearrangements.  Figure was adapted from Pieters et al. 200710. 
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chromosome abnormalities found in infant leukemias and in patients previously treated 
with DNA topoisomerase II inhibitors7, 8.  Compared to other leukemias, MLL fusion 
leukemias are particularly aggressive and have poor prognosis9, 10.  Event-free survival of 
leukemia patients bearing MLL translocations including t(9;11), t(4;11), and t(11;19) is 
significantly worse than for leukemia patients with wild-type MLL10 (Figure 1B). 
Wild-type MLL is a member of the Trithorax group of proteins.  MLL and other 
Trithorax proteins are involved in maintaining active gene expression.  These proteins 
antagonize the effect of Polycomb proteins, which are responsible for negatively 
regulating gene expression.  Mll homozygous null mice have defects in embryonic 
hematopoiesis and are embryonic lethal, suggesting a crucial role for MLL in 
development11. 
MLL is a very large protein that contains numerous functional domains3 (Figure 
1A).  Some domains are retained in the fusion protein including the AT-hooks and the 
repression domain.  The AT-hooks bind AT-rich DNA12.  The repression domain 
contains a CXXC domain, which binds non-methylated CpG DNA13.  Other domains 
such as the four plant homeodomains (PHD), transcriptional activation domain, and 
histone methyltransferase domain (SET) are not retained in the fusion protein that causes 
leukemia.  The individual MLL plant homeodomains, each of which fold into a structure 
that coordinates two zinc ions, have differing functions.  Some are required for 
homodimerization and another for binding to cyclophilin Cyp3314.  The activation 
domain interacts with the CREB-binding protein (CBP), which recruits transcriptional 
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activators and possesses intrinsic histone acetyltransferase activity15.  The SET domain is 
responsible for trimethylation of lysine 4 on histone H316, 17. 
MicroRNAs 
MicroRNAs (miRNAs, miRs) are approximately 22 nucleotide noncoding RNAs 
that function as antisense regulators of messenger RNAs (mRNAs)18.  Victor Ambros 
first discovered this class of small RNAs in C. elegans in 1993.  The lin-4 miRNA was 
shown to regulate the transition from the first larval stage to the second by 
downregulating lin-14 mRNA19.  In 2000, C. elegans let-7 miRNA was shown to regulate 
the transition from the late larval stage to adult cell fates20.  Today over 500 miRNA 
genes have been discovered in the human genome alone with notably high degrees of 
sequence conservation across species21. 
Many miRNAs display distinct temporal and spatial expression patterns, while 
others are constitutively transcribed18.  RNA Polymerase II transcribes miRNA genes22, 
which are located either within intergenic regions or within the introns of pre-mRNAs18 
(Figure 2A).  The transcribed pri-miRNA forms a stem loop structure.  Drosha cleaves 
the ends of the stem to produce 60-70 nucleotide pre-miRNAs23, 24.  Ran-GTP and 
Exportin5 facilitate active transport of the miRNA precursor from the nucleus to the 
cytoplasm25, 26.  Dicer then cleaves off the loop to reveal a miRNA:miRNA duplex27.  
Helicase unwinds the duplex and the miRNA strand whose 5’ end is more tightly paired 
is degraded28, 29.  The other miRNA strand, which represents the mature miRNA, is 
loaded on the RNA-induced silencing complex (RISC), where it scans for perfect or near  
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Figure 2. Maturation of MicroRNAs and Mechanisms for Downregulating Target 
Gene Expression 
Target mRNAs from loci 
unrelated to miRNA gene 
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(A) Maturation of miRNAs.  miRNA 
genes are transcribed by RNA 
polymerase II and then cleaved by 
Drosha.  The resulting pre-miRNA is 
transported into the cytoplasm, 
cleaved by Dicer, unwound by 
Helicase, and loaded onto the RISC 
complex.  Figure was adapted from 
Bartel 200422.  (B) and (C) 
Mechanisms utilized by miRNAs 
together with the RISC complex to 
downregulate target gene expression.  
Figures were adapted from Bartel 
200422.  (B) Extensive 
complementarity in the coding region 
or 3’ UTR specifies mRNA cleavage.  
(C) Short complementary segments in 
the 3’ UTR specifies translational 
repression. 
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perfect complementary mRNA sequences30.  The seed region, which encompasses 
nucleotides 2-7 of the miRNA, determines targeting of the miRNA to target mRNA31. 
miRNAs utilize different mechanisms to downregulate gene expression of their 
targets.  When there is a high degree of complementarity to the mRNA sequence, the 
target mRNA is cleaved within the miRNA-binding site, which results in decreased 
mRNA and protein levels24 (Figure 2B).  However, when there is a lower degree of 
complementarity to the mRNA sequence, translation is repressed, which results in 
decreased protein levels alone24 (Figure 2C).  Translation is thought to be repressed by 
the slowing or stalling of ribosomes or by the degradation of newly synthesized 
polypeptide. 
miRNAs are often abnormally expressed in many cancers including leukemias.  
For example, it was shown that MLL fusion proteins induce overexpression of miR-196b, 
which contributes to leukemogenesis32.  Determining which miRNAs are upregulated and 
downregulated in different subtypes of leukemia serves as a valuable diagnostic marker 
and may be useful in developing novel therapeutics33.  Techniques for replacing 
underexpressed miRNAs or inhibiting overexpressed miRNAs both in vitro and in vivo 
are currently being developed. 
miR-17-92 Cluster 
Although many miRNAs are present alone in the genome, some are located in 
clusters containing multiple miRNAs.  miRNA clusters are expressed together as a long 
precursor and are then processed into individual miRNAs34.  The miR-17-92 cluster is 
located within an 800 base-pair region of chromosome 13 within the third intron of a 
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primary transcript called C13orf2535 (Figure 3A).  The only known function of this 
transcript is to produce these miRNAs.  The miR-17-92 cluster encodes six miRNAs 
(miR-17, miR-18a, miR-19a, miR-20a, miR-19b, and miR-92a)36.  The miRNAs of the 
miR-17-92 cluster share a great deal of sequence homology, suggesting that they might 
be able to act collectively on a common target.  Gene duplications have produced miR-
106a-363 and miR-106b-25, two paralogs of the miR-17-92 cluster36.  miRNAs from 
these three clusters are placed into families based on conserved seed sequences31 (Figure 
3B). 
The miR-17-92 cluster is crucial for normal development of the heart, lungs, and 
immune system.  Knockout of this cluster has been shown to result in smaller embryos 
and immediate postnatal death due to ventricular septal defects in the heart and severely 
hypoplastic lungs37.  It has been demonstrated that the miR-17-92 cluster is highly 
expressed in embryonic lung tissue, but decreases over time38.  Additionally, this cluster 
is involved in promoting progression from pro-B to pre-B cells37. 
The miR-17-92 cluster acts as an oncogene39 and is overexpressed in 
hematopoietic malignancies and solid tumors including those originating from the breast, 
colon, lung, pancreas, prostate, and stomach40.  Several target genes with important roles 
in cell cycle progression, apoptosis, and angiogenesis have been identified and 
experimentally validated for this cluster.  The E2F family of transcription factors, which 
when expressed at high levels can induce apoptosis, is one such target41.  The miR-17-92 
cluster suppresses apoptosis by downregulating E2F1, E2F2, and E2F3.  The pro-
apoptotic gene Bim has also been shown to be a direct target of the miR-17-92 cluster42.   
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 Figure 3. The miR-17-92 Cluster 
!""#$%#
&#'$#
!"
#"
(A) The miR-17-92 cluster is located within an intron on chromosome 13.  Figure was 
adapted from Mendell 200836.  (B) miRNAs are aligned to show nucleotide sequence 
conservation.  Nucleotides that are conserved within a miRNA family are highlighted 
in blue.  The seed sequences (nucleotides 2-7) of each miRNA are in bold print. 
miR-17     CAAAGUGCUUACAGUGCAGGUAG 
miR-20a    UAAAGUGCUUAUAGUGCAGGUAG 
miR-20b    CAAAGUGCUCAUAGUGCAGGUAG 
miR-106a   AAAAGUGCUUACAGUGCAGGUAG 
miR-106b   UAAAGUGCUGACAGUGCAGAU 
miR-93     CAAAGUGCUCUUCGUGCAGGUAG 
 
miR-18a    UAAGGUGCAUCUAGUGCAGAUAG 
miR-18b    UAAGGUGCAUCUAGUGCAGUUAG 
 
miR-19a    UGUGCAAAUCUAUGCAAAACUGA 
miR-19b    UGUGCAAAUCCAUGCAAAACUGA 
 
miR-25     CAUUGCACUUGUCUCGGUCUGA 
miR-92a    UAUUGCACUUGUCCCGGCCUGU 
miR-363    AAUUGCACGGUAUCCAUCUGUA 
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Another target that has been validated is the cyclin-dependent kinase inhibitor p21, which 
is a negative regulator of the G1/S checkpoint43.  The miR-17-92 cluster is also known to 
downregulate expression of the tumor suppressor Pten44.  Finally, the anti-angiogenic 
proteins Tsp1 and CTGF are both negatively regulated by the miR-17-92 cluster45.  High 
levels of the miR-17-92 cluster have been shown to increase the number of leukemia 
stem cells, block differentiation, and enhance proliferation, while low levels of the miR-
17-92 cluster increase differentiation and decrease self-renewal46. 
Each subtype of acute myeloid leukemia and acute lymphoid leukemia has a 
unique miRNA expression profile.  The Chen group used bead-based miRNA expression 
profiling assays and TaqMan qPCR assays to show that the individual miRNAs of the 
miR-17-92 cluster are specifically upregulated in MLL rearranged leukemias, but not in 
the other subtypes that they tested47, 48.  Furthermore, this cluster is overexpressed in 
mouse leukemia cells with MLL-ELL and MLL-ENL fusions, although the expression is 
not quite as high as in the corresponding human leukemias49. 
WEE1 
Wee1 was first discovered in the fission yeast S. pombe as a mitotic inhibitor that 
controls the G2/M transition50.  Fission yeast deficient in Wee1 prematurely enter mitosis 
and divide at a small size.  The kinase was named “Wee” in reference to the small size of 
fission yeast lacking Wee1.  The catalytic domain of the human gene was cloned in 
199151, and the full-length gene was identified in 199552.  Wee1 has also been found in S. 
cerevisiae, Xenopus, Drosophila, and C. elegans. 
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Human WEE1 is a protein kinase that adds an inhibitory phosphate on Tyr15 of 
Cyclin dependent kinase 1 (Cdk1) during interphase53.  WEE1 holds Cdk1 in an inactive 
state until the G2/M transition of the cell cycle.  The function of WEE1 is antagonized by 
Cdc25 phosphatase, which removes the inhibitory phosphate at the onset of the M 
phase54. 
As shown in Figure 4, the pathway from inactive Cdk1 to fully active Cdk1 
requires several molecular players.  During interphase, Cdk1 associates with Cyclin B 
and is phosphorylated by Cdk-activating kinase (CAK) on Thr161.  Simultaneously, 
WEE1 phosphorylates Cdk1 on Tyr15, while the WEE kinase family member, MYT1, 
phosphorylates Cdk1 on Thr14 and Tyr15.  These inhibitory phosphorylations on Thr14 
and Tyr15 dominantly inhibit Cdk1 until the onset of mitosis, at which point Cdc25 
dephosphorylates Thr14 and Tyr15.  Cdk1 becomes active and triggers the rapid switch 
into mitosis54.  Upon entry into mitosis, WEE1 is inactivated by phosphorylation on 
Ser53 and Ser123 by Plk1 and Cdk155.  WEE1 is subsequently ubiquitinated and 
degraded55.  WEE1 levels remain low throughout M phase and G1 phase. 
The WEE family of kinases consists of WEE1, WEE2, and MYT1.  While WEE1 
and WEE2 solely phosphorylate Cdk1 on Tyr1553, MYT1 is a dual-specificity kinase that 
phosphorylates Cdk1 on both Thr14 and Tyr1556.  WEE1 and WEE2 are soluble proteins 
that localize to the nucleus56.  Conversely, MYT1 is membrane-associated and localizes 
to the cytoplasmic endoplasmic reticulum and Golgi apparatus56.  Importantly, in 
Xenopus, it was found that Wee1 is 10-fold more active than Wee257. 
11 
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During interphase, Cdk1 associates with Cyclin B.  Cdk-activating kinase (CAK) then 
adds an activating phosphate to Cdk1 on Thr161.  WEE1 adds an inhibitory phosphate 
to Cdk1 on Tyr15, while MYT1 adds two inhibitory phosphates to Cdk1 on Thr14 and 
Tyr15.  At the onset of mitosis, Cdc25 phosphatase removes the inhibitory phosphates, 
thereby fully activating Cdk1 and promoting mitosis.%
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The kinase domain of WEE1 is highly conserved across WEE family members.  
All WEE family members possess five conserved amino acid residues within their kinase 
domain that are unique to this family of kinases58.  The noncatalytic regions of these 
proteins are important for regulation, protein-protein interactions, and subcellular 
localization. 
miR-195 was recently shown to target two sites in the 3’ UTR of WEE1 in human 
embryonic stem cells59.  Since WEE1 levels control the rate of human embryonic stem 
cell division, downregulation of WEE1 by miR-195 promotes the cell cycle and increases 
cell proliferation59.  This study was the first to show a miRNA regulating WEE1.  
Nevertheless, it is still important to discover novel miRNAs that target WEE1.  It is 
conceivable that in different types of cells, other unique miRNAs target WEE1 for 
downregulation.  For this reason, we set out to validate WEE1 as a target of the miR-17-
92 cluster.
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CHAPTER 2 
METHODS 
MicroRNA Target Gene Prediction 
 Prediction algorithms including TargetScan (www.targetscan.org), MicroCosm 
Targets (www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5), PicTar (pictar.mdc-
berlin.de), and miBridge (sitemaker.umich.edu/mibridge/target_predictions) were used to 
predict potential biological targets of the miR-17-92 cluster. 
Cloning of Wild-Type Luciferase Reporter Construct 
 In order to amplify the 3’ UTR of WEE1 (NM_003390.3), the following PCR was 
set up: 40.1 uL dH2O, 5 uL 10x Cloned Pfu buffer, 0.4 uL 25 mM dNTPs, 1 uL 1ug/uL 
human genomic DNA, 1.25 uL 10 uM Forward Primer (Table 1), 1.25 uL 10 uM Reverse 
Primer (Table 1), 1 uL Cloned Pfu DNA Polymerase (Stratagene, Catalog #600159-81).  
The PCRs were run in the PCR Express Thermal Cycler (Hybaid) according to the 
following protocol: one cycle of 95°C for 45 seconds, 40 cycles of 95°C for 45 seconds, 
62.6°C for 45 seconds, 72°C for 3 minutes, one cycle of 72°C for 10 minutes, and hold at 
4°C.  The band at 939 bp was cut out and gel extracted using the QIAEX II Gel 
Extraction Kit (Qiagen, Catalog #20051). 
Table 1. Primers used to amplify the 3’ UTR of WEE1 from human genomic DNA 
Amplicon Primers (5’ to 3’) 
WEE1 3’ UTR 
(nucleotides 2418 - 3356 
of NM_003390.3) 
Forward: ATGTTACACCAGCCTTTCCAGGGT 
Reverse: AGACAATTAAGGTAAGCTCAGAGTGA 
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In order to add restriction sites to the ends of the above PCR product to facilitate 
cloning into the reporter vector, the following PCR was set up: 40.1 uL dH2O, 5 uL 10x 
Cloned Pfu buffer, 0.4 uL 25 mM dNTPs, 1 uL of the above PCR product, 1.25 uL 10 
uM Forward Primer (Table 2), 1.25 uL 10 uM Reverse Primer (Table 2), 1 uL Cloned Pfu 
DNA Polymerase.  The PCRs were run according to the following protocol: one cycle of 
95°C for 45 seconds, 40 cycles of 95°C for 45 seconds, 65.2°C for 45 seconds, 72°C for 
3 minutes, one cycle of 72°C for 10 minutes, and hold at 4°C.  The band at 969 bp was 
cut out and gel extracted. 
Table 2. Primers used to add flanking restriction sites to the 3’ UTR of WEE1 
Amplicon Primers (5’ to 3’) 
WEE1 3’ UTR 
(nucleotides 2418SpeI - 
3356HindIII) 
Forward: TCTCTCTCTACTAGTATGTTACACCAGCCTTTCCAGGGT 
Reverse: TCTCTCTCTAAGCTTAGACAATTAAGGTAAGCTCAGAGTGA 
 
 The 3’ UTR of WEE1 that was now flanked by SpeI and HindIII restriction sites 
was digested with SpeI and HindIII at 37°C for 2 hours along with the pMIR-REPORT 
Luciferase vector (Applied Biosystems, Catalog #AM5795).  The gel extracted digests 
were then ligated using T4 DNA Ligase (New England Biolabs, Catalog #M0202L) at 
16°C overnight to create a construct with the 3’ UTR of WEE1 immediately following 
the luciferase gene.  The ligation was electroporated into homemade DH10! 
Electrocompetent Cells using 1 uL ligation reaction and 20 uL cells using the following 
electroporator settings: 4 k" resistance, 330 µF capacitance.  The transformants were 
miniprepped using the GeneJET Plasmid Miniprep Kit (Fermentas, Catalog #K0503).  
The clone was confirmed by sequencing (ACGT, Inc.). 
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Cloning of Mutant Luciferase Reporter Constructs 
 In order to mutate the putative miR-17-92 binding sites in the 3’ UTR of WEE1, 
three mutant luciferase reporter constructs were generated.  For one of the constructs, the 
putative miR-17, miR-20a, and miR-18a target site was mutated.  In another of the 
constructs, the putative miR-19a and miR-19b target site was mutated.  The third mutant 
construct had all the putative miR-17-92 target sites mutated. 
 To produce the construct with the putative miR-17, miR-20a, and miR-18a target 
site mutated (referred to as miR-17 Mut), a modified site-directed mutagenesis protocol 
with non-overlapping primers was used to set up the following PCR using an error proof 
polymerase: 32.5 uL dH2O, 10 uL 5x Phusion HF Buffer, 1 uL 10 mM dNTPs, 2.5 uL 10 
uM Forward Primer (Table 3), 2.5 uL 10 uM Reverse Primer (Table 3), 1 uL 10 ng/uL 
template (wild-type luciferase reporter construct), 0.5 uL Phusion DNA Polymerase 
(Finnzymes, Catalog #F-530S).  The PCRs were run according to the following Touch 
Down PCR protocol: one cycle of 98°C for 30 seconds, 20 cycles of 98°C for 10 seconds, 
touch down from 60°C to 50°C in 0.5°C increments for 30 seconds, 72°C for 8 minutes, 
25 cycles of 98°C for 10 seconds, 50°C for 30 seconds, 72°C for 8 minutes, one cycle of 
72°C for 10 minutes, and hold at 4°C.  The PCR product was DpnI treated at 37°C for 1 
hour to digest the parental DNA template.  It was then electroporated into DH10! 
Electrocompetent Cells using 1 uL PCR product and 20 uL cells.  The transformants were 
miniprepped, and the plasmid DNA was sequenced.  Since stray mutations can be 
introduced during site-directed mutagenesis, the mutated region was ligated into the 
16 
 
pMIR-REPORT Luciferase vector using the SpeI and HindIII restriction sites used 
previously. 
Table 3. Primers used to mutate the putative miR-17, miR-20a, and miR-18a target 
site in the 3’ UTR of WEE1 
Amplicon Primers (5’ to 3’) 
Luciferase WEE1 3’ 
UTR miR-17 Mut pMIR-
REPORT 
Forward: GACTTGTATATCCCACTGGGAGACAGGGGTAGGCATTGCA 
TGAACCATGGGATG 
Reverse: GCCAATCAATGTTAATAAAACACAAGTCAAAGACAATGTA 
CCACATGTTTTAGACC 
 
To generate the construct with the putative miR-19a and miR-19b target site 
mutated (referred to as miR-19 Mut) and the construct with all the putative miR-17-92 
target sites mutated (referred to as miR-17,19 Mut), the following PCRs were set up: 39.5 
uL dH2O, 5 uL 10x Cloned Pfu buffer, 1 uL 10 mM dNTPs, 1 uL 10 ng/uL template 
(wild-type luciferase reporter construct or miR-17 Mut), 1.25 uL 10 uM Forward Primer 
(Table 4), 1.25 uL 10 uM Reverse Primer (Table 4), 1 uL Cloned Pfu DNA Polymerase.  
The PCRs were run according to the following protocol: one cycle of 95°C for 45 
seconds, 40 cycles of 95°C for 45 seconds, gradient from 55°C to 70°C for 45 seconds, 
72°C for 2 minutes, one cycle of 72°C for 10 minutes, and hold at 4°C.  The PCR 
products from all three annealing temperatures were pooled together and PCR purified.  
Each of the inserts and the pMIR-REPORT Luciferase vector were digested with SpeI 
and HindIII at 37°C for 2 hours.  The gel extracted digests were then ligated overnight at 
16°C using a 3:1 molar ratio of insert to vector.  The ligations were electroporated into 
homemade DH10! Electrocompetent Cells using 2 uL ligation reaction and 20 uL cells.  
The transformants were miniprepped and all clones were confirmed by sequencing. 
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Table 4. Primers used to mutate the putative miR-19a and miR-19b target site in the 
3’ UTR of WEE1 
Amplicon Primers (5’ to 3’) 
Luciferase WEE1 3’ 
UTR miR-19 Mut pMIR-
REPORT 
Forward: TCTCTCTCTACTAGTATGTTACACCAGCCTTTCCAGGGT 
Reverse: CCTTTATTAAGCTTAGACAATTAAGGTAAGCTCAGAGTGAC 
TTTTAATATGCCAATCAATGTTAATAAAACACAAGTCAAAGACAAT 
GTACCACATGTTTTAGACC 
Luciferase WEE1 3’ 
UTR miR-17,19 Mut 
pMIR-REPORT 
Forward: TCTCTCTCTACTAGTATGTTACACCAGCCTTTCCAGGGT 
Reverse: CCTTTATTAAGCTTAGACAATTAAGGTAAGCTCAGAGTGAC 
TTTTAATATGCCAATCAATGTTAATAAAACACAAGTCAAAGACAAT 
GTACCACATGTTTTAGACC 
 
Luciferase Reporter Assays 
 The wild-type and mutant luciferase reporter constructs as well as miR-17 
MSCV-PIG (Jianjun Chen, University of Chicago), miR-17-19b MSCV-PIG (J. Chen), 
miR-17-92 MSCV-PIG (J. Chen), MSCV-PIG (J. Chen), and pRL-TK (Promega, Catalog 
#e2241) were midiprepped using the Plasmid Midi Kit (Qiagen, Catalog #12145). 
 60,000 HEK293T cells were plated into each of 16 wells of a 24-well plate (TPP, 
Catalog #92024).  Each well was transfected 24 hours later using 6 ng control vector 
(pRL-TK), 120 ng Luciferase WEE1 3’ UTR (Wild-Type, miR-17 Mut, miR-19 Mut, or 
miR-17,19 Mut), and 600 ng miRNA (miR-17, miR-17-19b, miR-17-92, or Empty 
Vector).  The CalPhos Mammalian Transfection Kit (Clontech, Catalog #631312) was 
used for the transfections.  The medium was removed from each well the following day 
and replaced with fresh complete medium (DMEM (HyClone), 10% FBS, and 1% 
Pen/Strep). 
 The reporter assay was performed using the Dual-Luciferase Reporter Assay 
System (Promega, Catalog #E1910).  42 hours after transfection, the medium was 
removed from each well of the 24-well plate and the cells were gently washed with 200 
uL sterile 1x PBS.  100 uL 1x Passive Lysis Buffer (1600 uL dH2O, 400 uL 5x Passive 
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Lysis Buffer) was added to each well and the plate was rocked on a rocking platform at 
room temperature for 15 minutes.  Since the experiment was performed in triplicate, three 
20 uL aliquots of each of the 16 cell lysates were transferred to a white round-bottom 96-
well plate (Costar).  The plate was centrifuged at 1500 rpm for 5 minutes at room 
temperature to bring the cell lysates to the bottom of the wells. 
 Using the Microplate Luminometer (Veritas), both injectors were flushed three 
times with dH2O, three times with 70% Ethanol, three times with dH2O, and then three 
times with air.  The first injector was primed with Luciferase Assay Reagent II 
(lyophilized Luciferase Assay Substrate in Luciferase Assay Buffer II) and the second 
injector was primed with Stop & Glo Reagent (48 uL 50x Stop & Glo Substrate, 2352 uL 
Stop & Glo Buffer).  The assay was run using the luminometer, which dispensed 100 uL 
Luciferase Assay Reagent II into each well, measured firefly luciferase, dispensed 100 uL 
Stop & Glo Reagent into each well, and measured Renilla luciferase.  After the run, both 
injectors were flushed again.  The data was analyzed by determining the relative 
luciferase (firefly luciferase: Renilla luciferase) and normalizing to the wild-type 
luciferase reporter.  The experiment was performed in triplicate and repeated three times. 
Cell Culture 
 Four MLL fusion leukemia cell lines (MV-4-11, RS4;11, THP-1, MonoMac6), 
three non-MLL fusion leukemia cell lines (K-562, HL-60, U-937), and one non-leukemia 
cell line (HEK293T) were thawed from liquid nitrogen.  MV-4-11, K-562, and HL-60 
cells were cultured in IMDM (Gibco), 10% FBS, and 1% Pen/Strep.  RS4;11, THP-1, 
MonoMac6, and U-937 cells were cultured in RPMI-1640 (HyClone), 10% FBS, 1% 
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Pen/Strep, and 0.05 mM 2-mercaptoethanol.  HEK293T cells were cultured in DMEM 
(HyClone), 10% FBS, and 1% Pen/Strep.  All cells were cultured in a 37°C incubator 
with 5% carbon dioxide.  Each cell line was expanded from a 10 cm2 flask to two 75 cm2 
flasks.  The cell pellets were resuspended in 3 mL sterile 1x PBS and then counted using 
the Bright Line Counting Chamber (Hausser Scientific Company). 
For TaqMan MicroRNA Assays, 2,500,000 cells were aliquoted per microfuge 
tube for each cell line.  The cell pellets were resuspended in 500 uL TRI Reagent (Sigma, 
Catalog #T9424) by repeated pipetting.  The resuspended cell lysates were stored at -
80°C until RNA was isolated. 
For Western blotting, 1,000,000 cells were aliquoted per microfuge tube for each 
cell line.  Cell pellets were incubated on ice for immediate use in nuclear and cytoplasmic 
protein extraction. 
RNA Isolation and cDNA Synthesis 
 RNA was isolated from MV-4-11, RS4;11, THP-1, MonoMac6, K-562, HL-60, 
U-937, and HEK293T cells according to the manufacturer’s protocol (Sigma).  To 
summarize, cells that had been resuspended in TRI Reagent and stored at -80°C were 
briefly thawed in a room temperature water bath.  The samples were then allowed to 
stand at room temperature for 5 minutes.  100 uL of chloroform was added to each 
sample and the tubes were shaken vigorously for 15 seconds.  The samples were allowed 
to stand at room temperature for 10 minutes.  The tubes were centrifuged at 12,000 x g 
for 15 minutes at 4°C.  The colorless aqueous phase (upper layer) containing the RNA 
was transferred to a fresh microfuge tube by pipetting.  250 uL of isopropanol was added 
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and mixed.  The samples were allowed to stand at room temperature for 10 minutes.  The 
tubes were centrifuged at 12,000 x g for 10 minutes at 4°C.  500 uL of 75% ethanol was 
added to the RNA pellet and vortexed.  The tubes were centrifuged at 7,500 x g for 5 
minutes at 4°C.  The supernatant was discarded and then the RNA pellet was air-dried in 
the hood for 10 minutes.  The RNA pellet was reuspended in 20 uL of RNase-free water.  
The tube was incubated in a 55°C water bath for 10 minutes with periodic mixing.  The 
isolated RNA was stored at -80°C. 
 cDNA was reverse transcribed from total isolated RNA using the TaqMan 
MicroRNA Reverse Transcription Kit (Applied Biosystems, Catalog #4366596) and 
primers specific to each miRNA from the TaqMan MicroRNA Assay Kit (Applied 
Biosystems).  10 ug of RNA was used for each reaction.  For each 15 uL reverse 
transcription reaction, the following components were combined on ice: 0.15 uL 100 mM 
dNTPs (with dTTP), 1 uL MultiScribe Reverse Transcriptase (50 U/uL), 1.5 uL 10x 
Reverse Transcription Buffer, 0.19 uL RNase Inhibitor (20 U/uL), 4.16 uL Nuclease-free 
water, 5 uL total RNA diluted to a concentration of 2 ng/uL (isolated from either MV-4-
11, RS4;11, THP-1, MonoMac6, K-562, HL-60, U-937, or HEK293T cells), and 3 uL RT 
primer (specific to either U6 snRNA (constitutively expressed control), miR-17, or miR-
19a).  The reactions were incubated on ice for 5 minutes and subsequently loaded in the 
PCR Express Thermal Cycler (Hybaid).  The following program was run: 16°C for 30 
minutes, 42°C for 30 minutes, 85°C for 5 minutes, and hold at 4°C.  The cDNA was 
stored at -20°C until the Real-Time PCR step. 
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TaqMan MicroRNA Assays 
 During the PCR amplification step, AmpliTaq Gold DNA polymerase was used to 
amplify target cDNA using sequence-specific primers.  For each 20 uL reaction, the 
following components were combined on ice: 10 uL TaqMan 2x Universal PCR Master 
Mix, No AmpErase UNG (Applied Biosystems, Catalog #4324018), 7.67 uL Nuclease-
free water, 1 uL 20x TaqMan MicroRNA Assay mix (specific to either U6 snRNA, miR-
17, or miR-19a), and 1.33 uL of the cDNA from the reverse transcription step.  Since 
reactions were performed in triplicate, 20 uL of complete PCR master mix was dispensed 
into each of three wells of a clear 96-well PCR plate.  The plate was sealed with an 
optical adhesive cover and centrifuged at 1500 rpm for 5 minutes.  Real-time PCR was 
performed using the ABI 7300 Real-Time PCR System (Applied Biosystems) using the 
following program: one cycle of 95°C for 10 minutes followed by 40 cycles of 95°C for 
15 seconds and 60°C for 60 seconds.  The data was analyzed with ABI Prism 7300 
software.  miR-17 and miR-19a expression levels were determined relative to U6 snRNA 
levels using the 2-##Ct method60.  Relative expression was arbitrarily normalized to MV-4-
11 expression levels.  The assay was performed in triplicate and repeated two to five 
times. 
Nuclear and Cytoplasmic Protein Extraction 
 All steps for nuclear and cytoplasmic protein extraction were performed on ice.  
1,000,000 cell aliquots from MV-4-11, RS4;11, THP-1, MonoMac6, K-562, HL-60, U-
937, and HEK293T cells that were pelleted according to the protocol above were 
resuspended in 400 uL cold Buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM 
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EDTA, 1 mM DTT, 1:100 Protease inhibitor cocktail (Sigma, Catalog #P8340)) by gentle 
pipetting.  The cells were allowed to swell on ice for 15 minutes.  25 uL of 10% Nonidet 
NP-40 (Calbiochem, Catalog #492015) was added and then the tubes were vigorously 
vortexed for 10 seconds.  The tubes were centrifuged at 14,000 rpm for 15 minutes at 
4°C.  The supernatants containing the cytoplasmic extracts were snap frozen in 30 uL 
aliquots and stored at -80°C until further analysis.  The nuclear pellet was resuspended in 
50 uL ice-cold Buffer C (20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM DTT, 
1:100 Protease inhibitor cocktail (Sigma, Catalog #P8340)).  The tubes were vigorously 
rocked for 15 minutes on a rotator (Glas-Col) at 4°C and then centrifuged at 14,000 rpm 
for 5 minutes at 4°C.  The supernatants containing the nuclear extracts were snap frozen 
in 30 uL aliquots and stored at -80°C until further analysis. 
Western Blot Analysis 
 SDS-polyacrylamide (10%) gels (10% Bottom-Resolving; 4% Top-Stacking) with 
ten wells each were poured.  The protein samples were prepared by combining 30 uL 
cytoplasmic or nuclear extracts with 10 uL Sample Loading Buffer (2.5 mL 1 M Tris pH 
6.8, 1 g SDS, 0.05 g Bromophenol Blue, 5 mL Glycerol, 2.5 mL H2O, 500 mM DTT).  
The samples were vortexed, boiled at 95°C for 5 minutes, briefly centrifuged, and then 
loaded in the wells.  10 uL of Precision Plus Protein Kaleidoscope Standard (Bio-Rad, 
Catalog #161-0375) was loaded as a marker.  The gels were electrophoresed at 150 V, 0.5 
A for 65 minutes using 1x Running Buffer (5x Running Buffer: 15.1 g Tris base, 94 g 
Glycine, 50 mL 10% SDS, final volume brought up to 1 L using dH2O). 
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 Immobilon Transfer Membranes (Millipore, Catalog #IPVH00010) were pre-
incubated with methanol for 5 minutes and then washed twice with dH2O.  The 
membranes and gels were then equilibrated in 1x CAPS Buffer (100 mL 10x CAPS 
Buffer (22.13 g CAPS, final volume brought up to 1 L using dH2O, pH 11.0), 100 mL 
Methanol, 800 mL dH2O) for 25 minutes.  Gels were transferred to membranes at 70 V, 
0.5 A for 2 hours using 1x CAPS Buffer. 
 The membranes were each blocked in 5% blocking solution (TBS-T (75 mL 2 M 
NaCl, 20 mL 1 M Tris pH 7.5, 904 mL dH2O, 1 mL Tween-20), 5% w/v BSA) for 1 hour 
at room temperature on the Belly Dancer (Stovall Life Science).  The membranes were 
then incubated in primary antibody mixture (TBS-T, 5% w/v BSA, WEE1 rabbit 
polyclonal antibody (Cell Signaling, Catalog #4936, 1:1000 dilution)) with gentle 
shaking on the Orbitron Rotator II (Boekel Scientific) at 4°C overnight.  The membranes 
were washed three times for 10 minutes each with 15 mL TBS-T.  The membranes were 
then incubated in secondary antibody mixture (TBS-T, 5% w/v BSA, ECL Anti-Rabbit 
IgG-HRP Antibody (GE Healthcare, Catalog #NA934V, 1:3000 dilution)) for 2 hours at 
room temperature on the Belly Dancer.  The membranes were washed five times for 15 
minutes each with 15 mL TBS-T. 
 Using the SuperSignal West Pico Chemiluminescent Substrate Kit (Thermo 
Scientific, Catalog #34078), the Stable Peroxide Solution and the Luminol Enhancer 
Solution were mixed at a 1:1 ratio to prepare the substrate working solution.  The 
membranes were incubated with substrate working solution for 5 minutes at room 
temperature on the Belly Dancer.  The excess reagent was drained and the membranes 
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were wrapped in clear plastic wrap.  The membranes were developed using the FujiFilm 
LAS-3000 Luminescent Image Analyzer with Image Reader LAS-3000 software. 
In order to normalize for loading, the membranes were washed two times for 5 
minutes each with 15 mL TBS-T and then stripped by performing two 10 minute 
incubations with 15 mL Mild Stripping Buffer (15 g Glycine, 1 g SDS, 10 mL Tween-20, 
final volume brought up to 1 L using dH2O, pH 2.2).  The membranes were subsequently 
washed two times for 10 minutes each with 15 mL PBS followed by two washes for 5 
minutes each with 15 mL TBS-T.  The membranes were blocked with 5% blocking 
solution as described above and then incubated with the appropriate primary and 
secondary antibody mixtures.  !-Actin mouse monoclonal antibody (Sigma, Catalog 
#A5441, 1:5000 dilution) was used as the loading control primary antibody followed by 
ECL Anti-Mouse IgG-HRP Antibody (GE Healthcare, Catalog #NA931V, 1:3000 
dilution).  Band intensity from Western blot images was quantified using MultiGauge 
V3.0 software (FujiFilm) by subtracting background from band intensity.  WEE1 
expression was determined relative to !-Actin expression and was arbitrarily normalized 
to MV-4-11 expression levels.  The experiment was repeated twice.
 25 
CHAPTER 3 
RESULTS 
Aim: Determine whether WEE1 is a bona fide target of the miRNAs 
within the miR-17-92 cluster in MLL fusion leukemias 
 
It was recently shown that overexpression of the miR-17-92 cluster is a signature 
of MLL fusion leukemias48.  Because leukemias caused by rearrangement of the MLL 
gene are particularly aggressive and have poor prognosis, we predict that identification of 
mRNA transcripts targeted for downregulation by this miRNA cluster will shed light on 
novel molecular targets for this disease. 
Bioinformatic miRNA target gene prediction algorithms were used to predict 
potential targets of miR-17, miR-18a, miR-19a, miR-20a, miR-19b, and miR-92a.  
TargetScan predicts targets by searching for sites within human untranslated regions that 
match the seed region of miRNAs.  MicroCosm Targets functions by identifying high 
complementarity between miRNAs and 3’ UTRs while favoring complementarity in the 
seed region.  PicTar predicts targets of human miRNAs based on conservation of the 
target sequence across species.  miBridge searches for both 5’ UTR and 3’ UTR target 
sites in the same mRNA. 
For each miRNA of the cluster, we compiled a list of the thirty target genes with 
the highest total context score from TargetScan, the twenty target genes with the lowest 
P-value from MicroCosm Targets, the twenty target genes with the highest PicTar score 
from PicTar, and all predicted target genes from miBridge.  The data was synthesized to 
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assemble a list of gene targets that appeared in more than one prediction program.  Both 
MicroCosm Targets and miBridge predicted WEE1 to be a high probability target of 
miR-17 and miR-20a.  WEE1 also was identified as a likely target of miR-18a, miR-19a, 
and miR-19b in one prediction program each. 
The putative miR-17-92 target sites within the 3’ UTR of WEE1 are shown in 
Figure 5A.  Since miR-17, miR-20a, and miR-18a are highly homologous, it is not 
surprising that they are all predicted to target the same region in the 3’ UTR of WEE1.  
Similarly, miR-19a and miR-19b share a common target site.  The predicted alignment 
between WEE1 mRNA and each of the individual miRNAs of the cluster shows that there 
is a high degree of sequence complementarity within each paring especially in the seed 
region (Figure 5B).  We hypothesized that the cluster exerts combinatorial control on this 
target, thereby amplifying the effects of downregulation.  The goal of this aim is to 
elucidate whether WEE1 is a valid target of miR-17-92 in MLL fusion leukemias. 
Determination of whether miR-17-92 Specifically 
Targets the 3’ Untranslated Region of WEE1 
 
A study published earlier this year (after my project had been initiated) 
demonstrated that relative luciferase activity decreased by 21% when a luciferase reporter 
construct containing the 3’ UTR of WEE1 was co-transfected with miR-17 compared to 
when a luciferase reporter construct without the 3’ UTR was co-transfected with miR-
1761.  Similarly, the authors found a 15% reduction in luciferase activity with miR-20a61.  
While these results suggest that WEE1 is a target of miR-17 and miR-20a, they fail to 
identify the specific region of binding within the 3’ UTR and also neglect to investigate 
whether the rest of the miR-17-92 cluster exerts a regulatory effect on WEE1. 
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 Figure 5. Predicted miR-17-92 Binding Sites in the 3’ UTR of WEE1 
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(A) Sequence of WEE1.  The protein coding sequence is indicated in blue and the 3’ 
UTR is the region from the stop codon to the poly-A tail.  The putative miR-17-92 
target sites are highlighted in yellow.  (B) Predicted alignment between WEE1 mRNA 
and miR-17, miR-20a, miR-18a, miR-19a, and miR-19b.  The microRNA seed 
sequence is indicated in pink. 
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To establish whether WEE1 is a biological target of the entire miR-17-92 cluster 
and to determine the specific regions being targeted, we performed a luciferase reporter 
assay along with mutagenesis studies.  First, the 3’ UTR of WEE1 with the putative miR-
17-92 binding sites intact was amplified from human genomic DNA and cloned into the 
pMIR-REPORT Luciferase vector immediately following the luciferase gene (Figure 
6A).  We also generated three mutant versions of the reporter construct that disrupt 
binding between the miRNA and the mRNA by specifically mutating the six nucleotides 
where the seed region of the miRNA is predicted to bind.  Each guanine was converted to 
a thymine and vice versa.  Each cytosine was converted to an adenine and vice versa.  
One mutant possesses mutations in the putative miR-17, miR-20a, and miR-18a target 
site while another mutant contains mutations in the putative miR-19a and miR-19b target 
site (Figure 6A).  The third mutant has all the putative miR-17-92 target sites mutated 
(Figure 6A). 
We co-expressed the wild-type or one of three mutant reporter constructs with 
miR-17, miR-17-19b, miR-17-92, or empty vector in HEK293T cells.  Renilla luciferase, 
which was under the control of the HSV TK promoter, was also co-expressed for each 
condition as a control.  42 hours after transfection, the cells were lysed and firefly and 
Renilla luciferase activity were measured.  Firefly luciferase activity was normalized 
relative to Renilla luciferase activity to control for differences in transfection efficiency.  
Results are presented from one representative experiment performed in triplicate.  Three 
independent experiments were conducted. 
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 Figure 6. Luciferase Reporter and Mutagenesis Assays 
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(A) Schematic of wild-type and mutant luciferase reporter constructs.  (B)-(E) Relative 
luciferase activity measured 42 hours after the co-transfection of one of the reporter 
constructs with miR-17 (B), miR-17-19b (C), miR-17-92 (D), or empty vector (E) 
along with Renilla luciferase in HEK293T cells.  The data is presented as relative 
firefly luciferase: Renilla luciferase normalized to the wild-type construct, with error 
bars showing standard deviation.  * p<0.05; ** p<0.01; *** p<0.001. 
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Since the alignment score between WEE1 and the individual miRNAs of the miR-
17-92 cluster is high, we hypothesized that WEE1 is a physiological target of miR-17-92.  
If WEE1 is in fact a target, when the wild-type reporter construct is co-expressed with 
any of the miRNAs of the cluster, the miRNA will bind to the 3’ UTR and repress 
translation of luciferase, resulting in low luminescence.  On the other hand, co-expression 
of a reporter plasmid containing mutated binding sites with one of the miRNAs of the 
cluster will inhibit binding and result in relatively higher luminescence. 
As seen in Figure 6B, when the putative miR-17 binding site is mutated in the 
reporter construct (miR-17, miR-20a, and miR-18a target site mutated or all target sites 
mutated), relative luciferase activity increases upon overexpression of miR-17 as 
compared to when the putative binding site is intact (wild-type or miR-19a and miR-19b 
target site mutated).  There is a statistically significant increase in luciferase activity 
(p<0.001) in both cases.  This indicates that WEE1 is a valid target of miR-17.  Because 
luciferase activity does not increase when the putative miR-19a and miR-19b site is 
mutated, we can deduce that miR-17 specifically targets the predicted miR-17 target site 
(Figure 6B). 
The miR-17-19b construct expresses all of the miRNAs present in the miR-17-92 
cluster, except for miR-92a.  All five of the miRNAs within miR-17-19b are predicted to 
target WEE1.  When the miR-17, miR-20a, and miR-18a target site is mutated in the 
reporter construct, overexpression of miR-17, miR-20a, and miR-18a leads to an increase 
in luciferase activity (Figure 6C).  This suggests that WEE1 is a target of at least one of 
these miRNAs.  Notably, the change in luciferase activity is quite similar to the change in 
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luciferase activity for miR-17 alone, indicating that perhaps miR-20a and miR-18a are 
less important than miR-17 in regulating WEE1.  When the miR-19a and miR-19b target 
site is mutated in the reporter construct, overexpression of miR-19a and miR-19b causes 
a small, but statistically significant increase in luciferase activity (Figure 6C).  This 
implies that WEE1 is a target of miR-19a, miR-19b, or both.  Finally, when all of the 
predicted target sites are mutated, co-expression of all five miRNAs increases luciferase 
activity by a larger margin, indicating that possibly all five miRNAs collectively regulate 
WEE1 expression (Figure 6C). 
As shown in Figure 6D, co-expression of the entire miR-17-92 cluster with any of 
the mutant reporter constructs results in a statistically significant increase in luciferase 
activity.  Since the reporter construct with all of the predicted target sites mutated had the 
greatest increase in luciferase activity relative to the wild-type construct, this provides 
further evidence that the entire miR-17-92 cluster is acting jointly to downregulate WEE1 
expression. 
Surprisingly, there were small, but statistically significant increases in luciferase 
activity in the presence of the empty vector (Figure 6E).  This observation led us to 
predict that high endogenous miR-17-92 levels in HEK293T cells could be exerting an 
effect on this assay.  It was later confirmed by TaqMan MicroRNA Assays that 
HEK293T cells have relatively high endogenous levels of miR-17 and miR-19a (Figure 
7A, B). 
From the luciferase reporter and mutagenesis assays, we can conclude that miR-
17 specifically targets nucleotides 465 to 487 of the 3’ UTR of WEE1, which leads to 
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downregulation of WEE1.  miR-20a and miR-18a also conceivably regulate WEE1 by 
targeting the same region in the 3’ UTR, albeit to a lesser extent than miR-17.  Finally, 
miR-19a and miR-19b exert control on WEE1 by targeting nucleotides 1069 to 1091 of 
the 3’ UTR, although this regulation is likely less influential than that of miR-17. 
Determination of miR-17-92 Expression Levels in MLL Fusion Leukemia 
Cell Lines Compared to Non-MLL Fusion Leukemia Cell Lines 
 
Previous studies have shown that the miR-17-92 cluster is particularly 
upregulated in samples from patients with acute leukemias bearing MLL rearrangements 
compared to patient samples with other common translocations47, 48.  ChIP analysis 
showed that MLL fusion proteins upregulate expression of the miR-17-92 cluster by 
directly binding to the locus promoter region48.  From these prior studies, we 
hypothesized that overexpression of miR-17-92 would also be a signature of MLL fusion 
leukemia cell lines. 
To quantify endogenous miR-17-92 expression in MLL fusion leukemia cell lines 
and non-MLL fusion leukemia cell lines, we isolated RNA, synthesized cDNA using a 
looped reverse transcription primer specific to each miRNA, and performed TaqMan 
MicroRNA Assays using a variety of cell lines.  The MLL fusion leukemia cell lines 
included those with MLL-AF4 fusions (MV-4-11 and RS4;11) and MLL-AF9 fusions 
(THP-1 and MonoMac6).  These cell lines represent the most common MLL 
translocations.  The non-MLL fusion leukemia cell lines chosen included one with a 
BCR-ABL gene fusion (K-562), one with amplified c-Myc (HL-60), and a histiocytic 
lymphoma (U-937).  We also included a non-leukemia cell line (HEK293T) as a control. 
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We selected two representative miRNAs, miR-17 and miR-19a, to quantify.  miR-
17 was chosen because miR-17, miR-20a, and miR-18a have highly homologous 
sequences and are predicted to target the same site in the 3’ UTR of WEE1.  Similarly, 
since miR-19a and miR-19b differ by only one nucleotide and share the same target site, 
miR-19a was selected as the second representative miRNA.  Ubiquitously expressed U6 
snRNA served as the internal control.  The assay was performed in triplicate and repeated 
two to five times. 
Based on results from the bead-based miRNA expression profiling assay and the 
TaqMan qPCR assay47, 48, we expected the MLL fusion leukemia cell lines to have high 
levels of miR-17 and miR-19a and the non-MLL fusion leukemia cell lines and the non-
leukemia control cell line to have low expression of these two miRNAs. 
Surprisingly, our results showed no significant increase in miR-17 (Figure 7A) or 
miR-19a (Figure 7B) expression in the MLL fusion leukemia cell lines compared to the 
non-MLL fusion leukemia cell lines and the non-leukemia control.  The cell lines with 
the highest expression of these two miRNAs were HL-60 and U-937 cells, both of which 
are non-MLL fusion leukemia cells. 
From the TaqMan MicroRNA Assays, we can conclude that miR-17-92 
expression levels in leukemia cell lines are dependent on factors in addition to the 
presence of a MLL translocation. 
Determination of WEE1 Expression Levels in MLL Fusion Leukemia 
Cell Lines Compared to Non-MLL Fusion Leukemia Cell Lines 
 
Western blot analysis was conducted to examine endogenous WEE1 protein 
levels in MLL fusion leukemia cell lines and non-MLL fusion leukemia cell lines.  To  
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 Figure 7. Quantification of Endogenous miR-17 and miR-19a Levels 
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(A) Endogenous expression levels of miR-17 (A) and miR-19a (B) in four MLL fusion 
leukemia cell lines (MV-4-11, RS4;11, THP-1, MonoMac6), three non-MLL fusion 
leukemia cell lines (K-562, HL-60, U-937), and one non-leukemia cell line 
(HEK293T).  RNA was isolated from each cell line, cDNA was synthesized, and 
expression levels of miR-17 and miR-19a were quantified with TaqMan MicroRNA 
Assays.  Shown are average expression levels relative to U6 snRNA and normalized to 
MV-4-11.  Error bars indicate standard deviation. 
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enrich for WEE1, which localizes to the nucleus, nuclear and cytoplasmic proteins were 
extracted from the same panel of cell lines used for quantification of miR-17 and miR-
19a levels (MV-4-11, RS4;11, THP-1, MonoMac6, K-562, HL-60, U-937, and 
HEK293T).  Nuclear and cytoplasmic extracts were electrophoresed on SDS-
polyacrylamide gels, transferred to PVDF membranes, and probed for WEE1 expression 
using an antibody that is reactive with human WEE1.  The membranes were then stripped 
and re-probed for !-Actin as a loading control.  The nuclear WEE1 and !-Actin bands 
were quantified using MultiGauge V3.0 software.  Two independent experiments were 
performed and the results from one representative experiment are presented. 
We originally hypothesized that the MLL fusion leukemia cell lines, which we 
expected to have high miR-17-92 levels, would have low WEE1 expression if WEE1 
were indeed a target of miR-17-92.  Conversely, we predicted that the non-MLL fusion 
leukemia cell lines, which we expected to have low miR-17-92 levels, would have high 
WEE1 expression. 
Western blot analysis revealed that, as expected, WEE1 is present in the nucleus62 
(Figure 8A), but not in the cytoplasm (Figure 8C).  WEE1 expression from nuclear 
extracts was quantified relative to !-Actin expression (Figure 8B).  Notably, there was no 
connection between endogenous WEE1 expression and MLL rearrangement status.  For 
example, the cell lines with the highest relative expression of WEE1, MonoMac6 and 
THP-1, were in fact both MLL fusion leukemia cell lines.  Strikingly, the cell lines with 
the lowest relative expression of WEE1 were the same cell lines with the highest relative 
expression of miR-17 and miR-19a, namely HL-60 and U-937. 
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 Figure 8. Endogenous Nuclear and Cytoplasmic WEE1 Protein Expression 
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(A) Western blot analysis of endogenous WEE1 from nuclear extracts of the indicated 
cell lines.  A shorter exposure (upper) and longer exposure (lower) of the WEE1 blot 
are shown.  !-Actin served as a loading control.  (B) Quantification of WEE1 
expression levels from nuclear extracts relative to !-Actin levels.  Relative expression 
was normalized to MV-4-11.  Band intensity was quantified using MultiGauge V3.0 
software.  (C) Western blot analysis of endogenous WEE1 from cytoplasmic extracts 
of the same cell lines used in (A) and (B).  !-Actin was used as a loading control. 
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From the Western blot analysis, we can conclude that in the cell lines we tested, 
endogenous WEE1 expression is dependent on factors in addition to the presence of a 
MLL fusion protein. 
Determination of the Relationship between 
miR-17-92 Expression and WEE1 Expression 
 
We initially hypothesized that high endogenous expression of miR-17-92 in MLL 
fusion leukemia cell lines would correspond with low endogenous expression of WEE1 
in the same cell lines.  While we did not see a direct relationship between MLL 
rearrangement status and miR-17-92 expression, we were interested in discerning 
whether a relationship existed between miR-17-92 expression and WEE1 expression. 
Relative expression of miR-17 that was determined by TaqMan MicroRNA 
Assays was plotted against relative expression of WEE1 that was determined by 
quantification of Western blot analysis.  We observed a negative correlation between the 
two variables with a coefficient of determination (R2) of 0.6093 (Figure 9A).  In general, 
as miR-17 levels increased, there was a corresponding decrease in WEE1 expression 
levels.  Similarly, we saw a negative correlation between relative expression of miR-19a 
and relative expression of WEE1 with a coefficient of determination (R2) of 0.5388 
(Figure 9B).  This result strengthens our conclusion that WEE1 is a valid target of the 
miR-17-92 cluster. 
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 Figure 9. Negative Correlation between WEE1 Expression and miR-17 or 
miR-19a Expression 
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Scatter plot of relative expression of WEE1 versus relative expression of miR-17 (A) 
or miR-19a (B).  Each point on the graph represents a unique cell line (MV-4-11, 
RS4;11, THP-1, MonoMac6, K-562, HL-60, U-937, and HEK293T).  The best fit line 
in shown as well as the equation of the line and the coefficient of determination (R2). 
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CHAPTER 4 
DISCUSSION 
Identifying targets of the miR-17-92 cluster is important for expanding our 
understanding of the complex molecular pathways that regulate gene expression and are 
dysregulated in leukemia and cancer in general.  Previous studies have experimentally 
validated a range of gene targets of the miR-17-92 cluster in various systems.  The 
individual miRNAs of this cluster have been shown to promote cell proliferation by 
downregulating p2143 and Pten44, suppress apoptosis by downregulating E2Fs41 and 
Bim42, and induce angiogenesis in solid tumors by downregulating Tsp1 and CTGF45.  
Since combined haploinsufficiency of Bim and Pten only partially mimics the oncogenic 
effects of miR-17-92 overexpression44, it is likely that additional targets contribute to 
these effects.  As such, we were interested in seeking novel targets of the miR-17-92 
cluster.  In this study, we set out to ascertain which gene transcripts were being targeted 
for downregulation by the miR-17-92 cluster in MLL fusion leukemias. 
We used bioinformatic miRNA target gene prediction algorithms to predict 
additional targets of miR-17-92.  WEE1, a protein kinase that adds an inhibitory 
phosphate to Cdk1, was identified as a possible target of miR-17, miR-20a, miR-18a, 
miR-19a, and miR-19b.  According to MicroCosm Targets, among all the miRNAs 
predicted to target WEE1, miR-17 had the second highest score, miR-20a had the ninth 
highest score, and miR-18a had the thirtieth highest score.  It is conceivable, therefore, 
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that multiple miRNAs from the miR-17-92 cluster collectively regulate WEE1 
expression. 
Our objective for this thesis was to experimentally validate the computationally 
predicted target WEE1.  We hypothesized that overexpression of the miR-17-92 cluster 
in MLL fusion leukemias leads to downregulation of WEE1, which promotes cell cycle 
progression and eventually results in leukemia. 
 Luciferase reporter assays are considered the “gold standard” in validating 
miRNA gene targets44, 63, 64.  We performed luciferase reporter assays in which we co-
transfected a wild-type or mutant luciferase reporter construct with various combinations 
of miRNAs from the miR-17-92 cluster.  We observed statistically significant increases 
in luciferase activity when a putative miRNA binding site was mutated in the reporter 
construct compared to when the site was intact. 
From our experiments, it appeared as though miR-17 is the most crucial regulator 
of WEE1 expression.  The change in luciferase activity for miR-17, miR-20a, and miR-
18a together was quite similar to the change in luciferase activity for miR-17 alone, 
indicating that perhaps miR-20a and miR-18a are less important.  Furthermore, while the 
increase in luciferase activity for miR-19a and miR-19b was statistically significant, it 
was not as sizeable as for miR-17.  To better decipher the individual contribution of each 
miRNA of the miR-17-92 cluster to WEE1 regulation, it would be interesting to follow 
up these studies by expressing each miRNA individually in this assay. 
Unexpectedly, we observed small increases in luciferase activity in the presence 
of the empty vector.  This suggests that endogenous miR-17-92 expression in HEK293T 
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cells might be slightly affecting the assay.  It would be interesting to repeat this 
experiment in a cell line with low endogenous levels of miR-17 and miR-19a, for 
example, in K-562 cells.  These cells would have to be nucleofected with the appropriate 
constructs because they cannot be transfected easily. 
Overall, from the luciferase reporter assays, we were able to experimentally 
confirm our hypothesis that WEE1 is a bona fide target of the miR-17-92 cluster.  
Importantly, through mutagenesis studies, we found the specific region in the 3’ UTR of 
WEE1 that miR-17, miR-20a, and miR-18a target (nucleotides 465 to 487) and the 
specific region in the 3’ UTR of WEE1 that miR-19a and miR-19b target (nucleotides 
1069 to 1091). 
 TaqMan MicroRNA Assays are a useful technique for quantifying endogenous 
levels of miRNAs in tissues ranging from cell lines to patient samples65.  A panel of cell 
lines was selected for this study including MLL fusion leukemia cell lines (MV-4-11, 
RS4;11, THP-1, MonoMac6), non-MLL fusion leukemia cell lines (K-562, HL-60, U-
937), and a control non-leukemia cell line (HEK293T).  We isolated RNA from each of 
the cell lines, prepared cDNA, and then assayed for endogenous miR-17 and miR-19a 
expression using TaqMan MicroRNA Assays. 
Surprisingly, HL-60 and U-937, both of which are non-MLL fusion leukemia cell 
lines, displayed the highest expression of these two miRNAs.  This is not entirely 
unexpected, though, because HL-60 cells have amplification of the c-Myc gene, which 
has been shown to directly transactivate transcription of the miR-17-92 cluster41.  
42 
 
Likewise, U-937 cells are derived from lymphoma cells, and many lymphomas possess 
amplification of the human locus encoding the miR-17-92 cluster35. 
The difference between the relative miR-17-92 expression levels we observed and 
those that the Chen group observed47, 48 may be attributed to inherent differences in 
expression profiles between cell lines and patient samples.  The method of creating new 
cell lines requires immortalizing primary human cells, a process that can cause changes in 
gene expression66.  Interestingly, TaqMan qPCR data from the Chen group showed that 
patient samples better followed the expected trend of high miR-17-92 levels in MLL 
fusion leukemias and low miR-17-92 levels in non-MLL fusion leukemias than cell 
lines47, 48.  In fact, they found that miR-17 and miR-20a expression was high in all the 
leukemia cell lines they tested regardless of MLL rearrangement status47, 48.  While the 
Chen group tested ME1, KASUMI-1, and NB4 as their non-MLL fusion leukemia cell 
lines, we tested K-562, HL-60, and U-937 cells.  We did, however, have overlap in the 
MLL fusion leukemia cell lines tested.  Common cell lines included MV-4-11, THP-1, 
and MonoMac6.  The Chen group observed high expression of miR-17 and miR-20a in 
all three of these cell lines47, 48.  We also observed fairly high expression of miR-17 and 
miR-19a in these cell lines, but unlike the Chen group, we did not mean-center our 
expression data, which makes a direct comparison between the two sets of data difficult. 
To further validate WEE1 as a target of the miR-17-92 cluster, we conducted 
Western blot analysis to assess the relative endogenous expression of WEE1 across a 
panel of MLL fusion leukemia cell lines (MV-4-11, RS4;11, THP-1, MonoMac6), non-
MLL fusion leukemia cell lines (K-562, HL-60, U-937), and a control non-leukemia cell 
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line (HEK293T).  We hypothesized that cell lines with high expression levels of miR-17-
92 would express lower levels of WEE1. 
We chose to look at WEE1 protein expression using Western blot analysis rather 
than WEE1 mRNA expression using qRT-PCR because miRNA gene targeting always 
downregulates protein expression, but only sometimes downregulates mRNA expression.  
It allowed us to explore whether either of the mechanisms for downregulation, mRNA 
cleavage or translational repression, occurred.  mRNA cleavage takes place when the 
mRNA has extensive complementarity to the miRNA24, 67.  Translational repression 
occurs when there is insufficient complementarity for mRNA cleavage, but adequate 
complementarity at multiple sites within the 3’ UTR for translational repression24, 67.  
Translational repression is also the more common mechanism used by metazoan 
miRNAs.  Since the individual miRNAs of the miR-17-92 cluster are metazoan miRNAs 
and because there is not perfect complementarity between the miRNAs of the miR-17-92 
cluster and the 3’ UTR of WEE1, we hypothesized that WEE1 mRNA levels remained 
constant upon miRNA targeting, but WEE1 protein levels decreased. 
To enrich for WEE1, which localizes to the nucleus62, we prepared nuclear and 
cytoplasmic protein extracts.  As predicted, we detected WEE1 in the nuclear extracts, 
but not in the cytoplamic extracts.  Remarkably, the two cell lines with the highest 
endogenous expression of miR-17 and miR-19a, HL-60 and U-937, displayed the lowest 
endogenous expression of WEE1. 
Interestingly, WEE1 electrophoresed slower than expected.  While the predicted 
molecular weight for WEE1 is 72 kDa, product literature for the WEE1 antibody 
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indicates that the apparent molecular weight on SDS-polyacrylamide gels is typically 95 
to 100 kDa.  In our Western blot analysis, WEE1 was detected at approximately 150 kDa, 
which raises the possibility of WEE1 dimerization or the presence of post-translational 
modifications. 
 We were interested to see if a relationship existed between endogenous miR-17 or 
miR-19a expression and endogenous WEE1 expression.  Plotting the relative expression 
of miR-17 versus the relative expression of WEE1 revealed a negative correlation 
between the two variables.  A similar negative correlation was observed for the 
relationship between the relative expression of miR-19a and the relative expression of 
WEE1.  That is, as the expression of one of the two miRNAs increased, the expression of 
WEE1 decreased.  We concluded that the regulation was likely occurring at physiological 
levels because we observed this trend while studying endogenous expression rather than 
by overexpression. 
While the data indicates that there is a correlation between miR-17-92 levels and 
WEE1 expression levels, it does not necessarily imply causation between the variables.  
However, causation was established through the luciferase reporter assays, which showed 
that luciferase activity increased upon co-expression of the miR-17-92 cluster with a 
reporter plasmid containing mutations in all of the putative miR-17-92 binding sites.  
Nevertheless, observing a negative correlation between miR-17-92 and WEE1 in the cell 
lines we tested provides further evidence in support of WEE1 being a valid target of the 
miR-17-92 cluster. 
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According to the model shown in Figure 10A, when expression of the miR-17-92 
cluster is low, WEE1 is translated normally.  As such, WEE1 functions to prevent cells 
from entering mitosis until they are ready.  Conversely, when expression of the miR-17-
92 cluster is high, miR-17, miR-20a, or miR-18a bind to nucleotides 465 to 487 and miR-
19a or miR-19b bind to nucleotides 1069 to 1091 of the 3’ UTR of WEE1 (Figure 10B).  
It is conceivable that different molecules of WEE1 mRNA have different combinations of 
miRNAs from the miR-17-92 cluster bound at these target sites.  Together with the RISC 
complex, the miR-17-92 cluster represses translation of WEE1.  WEE1 is a critical 
regulator of the G2/M transition, one of the restriction checkpoints.  At each checkpoint, 
cell cycle progression stalls if flaws are detected.  Because WEE1 inhibits cell cycle 
progression, it is an anti-proliferative protein.  Consequently, downregulation of WEE1 
by the miR-17-92 cluster would have pro-proliferative functional effects. 
In summary, we have established WEE1 as a novel target of the entire miR-17-92 
cluster except for miR-92a.  Moreover, we have determined the exact location within the 
3’ UTR of WEE1 that miR-17, miR-20a, miR-18a, miR-19a, and miR-19b target.  While 
we did not observe a relationship between miR-17-92 expression and MLL rearrangement 
status in the cell lines we tested, we demonstrated a specific inverse relationship between 
endogenous miR-17-92 expression and endogenous WEE1 expression in these cell lines. 
The results from this project present several new possibilities for future 
investigations.  It remains to be determined the exact contribution of each miRNA from 
the miR-17-92 cluster to WEE1 regulation.  This can be established by studying each 
miRNA individually in a luciferase reporter assay.  To determine whether miR-17-92 is  
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 Figure 10. Model of the Regulation of WEE1 by the miR-17-92 Cluster 
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(A) In the absence of the miR-17-92 cluster, WEE1 is translated as normal and WEE1 
protein levels remain high.  (B) In the presence of high expression of the miR-17-92 
cluster in some types of leukemia, miR-17, miR-20a, or miR-18a bind to their target 
site in the 3’ UTR of WEE1 and miR-19a or miR-19b bind to their target site.  
Together with the RISC complex, the miR-17-92 cluster inhibits translation of WEE1, 
which corresponds to a decrease in WEE1 protein levels.  Since WEE1 inhibits cell 
cycle progression, downregulation of WEE1 promotes cell cycle progression and 
contributes to leukemogenesis. 
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regulating WEE1 by mRNA cleavage or by translational repression, it would be useful to 
investigate WEE1 mRNA levels by qRT-PCR.  If mRNA levels are unchanged by 
changes in miR-17-92 expression, one can deduce that downregulation is occurring via 
translational repression.  If, however, WEE1 mRNA levels co-vary with WEE1 protein 
levels, this would suggest that mRNA cleavage is occurring.  Additionally, it would be 
interesting to investigate the expression of WEE1 in samples from patients with different 
subtypes of leukemia to determine whether a negative correlation exists between miR-17-
92 and WEE1 in patient samples.  Another possible avenue for future research would be 
to explore whether WEE1 is a target of the miR-17-92 cluster in other types of cancers 
including solid tumors.  A positive finding would suggest that there are broader 
implications for this regulatory relationship.  It also remains to be resolved whether 
abnormal miRNA expression causes development of the cancer or whether the cancer 
causes abnormal miRNA expression. 
The conclusions from this research suggest that the miR-17-92 cluster and WEE1 
are potential therapeutic targets for leukemia.  Researchers are already working on 
developing efficient delivery mechanisms to administer antisense oligonucleotides to 
inhibit miRNAs such as the oncogenic miR-17-92 cluster68.  One of the challenges of this 
approach is that all of the miRNAs of the cluster would have to be inhibited 
simultaneously due to the functional redundancy of the cluster.  Furthermore, developing 
a mechanism to reintroduce WEE1 into leukemia patients with downregulated WEE1 
could prove beneficial in inhibiting uncontrolled cell proliferation.  It is my hope that 
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targeted cancer therapies such as these will continue to make their way from the bench to 
the bedside.
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